Faeth Therapeutics, Inc. (NasdaqCM: FTH)
Health Care · Biotechnology · US
$24.50
-5.88% today · +131.2% 1Y
Faeth Therapeutics, Inc. (NasdaqCM: FTH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $672.63M and employs 29 people.
Over the last twelve months the share price has gained 131.2%, trading between 7.45 and 42.14.
Tweenvest scores Faeth Therapeutics, Inc. across four factors: quality 35/100, value 90/100. Its strongest factor is value.
FTH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $672.63M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -82.46
- Dividend yield
- —
- Beta (5Y)
- -0.29
- 52-week high
- $42.14
- 52-week low
- $7.45
- Avg volume (3M)
- —
- Shares outstanding
- 25.84M
- Employees
- 29
- Next earnings
- —
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
- ISIN
- US81728A2078
- Founded
- 1999
- Listed since
- Feb 4, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MiMedx Group, Inc.NasdaqCM: MDXG | $680.70M | $4.76 | +1.93% |
| Aura Biosciences, Inc.NasdaqGM: AURA | $678.23M | $6.63 | +1.38% |
| Qurient Co., Ltd.KOSDAQ: A115180 | $676.80M | ₩22,350.00 | -9.70% |
| Sunmax Biotechnology Co., Ltd.TPEX: 4728 | $674.51M | NT$396.00 | +0.38% |
| Abbisko Cayman LimitedSEHK: 2256 | $665.94M | HK$7.89 | -9.83% |
| Beijing Bohui Innovation Biotechnology Group Co., Ltd.SZSE: 300318 | $646.39M | CN¥5.30 | +1.34% |
| Crescent Biopharma, Inc.NasdaqCM: CBIO | $638.16M | $14.69 | -1.48% |
| Medigen Vaccine Biologics CorporationTPEX: 6547 | $637.45M | NT$62.00 | +1.97% |
Figures last refreshed Oct 11, 2026.